Subscribe
shutterstock_1821779429_rafapress
rafapress / Shutterstock.com
10 February 2022GenericsAlex Baldwin

Lupin and Sun settle Bromsite patent suit after ruling

Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite (bromfenac) eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent